Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population.
Kitami, Toshimori, Fukuda, Sanae, Kato, Tamotsu et al. · Scientific reports · 2020 · DOI
Quick Summary
Researchers studied 48 ME/CFS patients and 52 healthy people in Japan to find biological markers of the disease. They tested blood samples, gut bacteria, immune cells, and sleep patterns, identifying 26 potential markers that differ between patients and healthy people. Three markers stood out as most important: certain types of white blood cells, gut bacteria composition, and fat-like molecules in the blood, which were especially linked to sleep problems in ME/CFS patients.
Why It Matters
This study is significant because ME/CFS currently lacks objective diagnostic tests and approved treatments. By identifying specific molecular patterns in blood and gut bacteria that distinguish ME/CFS patients from healthy people, this research offers hope for developing diagnostic blood tests and understanding disease mechanisms. The finding that sleep disruption correlates with specific metabolic and immune changes may eventually guide treatment strategies.
Observed Findings
26 potential molecular markers distinguished ME/CFS patients from healthy controls across metabolomics, immunology, and microbiome analyses.
Monocyte numbers, microbiome abundance, and lipoprotein profiles were the most informative discriminatory markers.
Lipoprotein and microbiome profiles showed the strongest correlation with sleep disruption in ME/CFS patients.
A different cluster of molecular markers correlated with cognitive fatigue parameters.
Sleep, lipoprotein, and microbiome changes appeared to occur early in disease course.
Inferred Conclusions
Sleep-related molecular changes represent a prominent pathophysiological feature of ME/CFS in the Japanese population studied.
Multiple biological systems (immune, metabolic, and microbial) are concurrently altered in ME/CFS, suggesting a complex, multi-system disease mechanism.
Lipoprotein and microbiome profiles warrant further investigation as potential early biomarkers for ME/CFS diagnosis and monitoring.
Remaining Questions
Do these molecular markers appear before symptom onset, or do they develop as a consequence of illness?
How well do these findings generalize to ME/CFS populations outside Japan with different genetic backgrounds and environmental exposures?
What This Study Does Not Prove
This study does not establish whether the identified markers cause ME/CFS or result from it—correlation does not prove causation. The findings may not apply to ME/CFS patients outside Japan due to genetic and environmental differences. The study's cross-sectional design cannot determine if these markers appear before symptom onset or how they change over the course of illness.